ACOG
Alpha Cognition IncHealthcare · $134M market cap
Verdict
We can't put a fair value on ACOG right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ACOG
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 22, 2026: 2 open-market purchases worth $266K. Why purchases matter
Purchases
Questions about ACOG
Are insiders buying ACOG?
Since Oct 22, 2026: 2 open-market purchases worth $266K.
How can I check ACOG's value myself?
Use the free Sticker Price calculator, already filled with ACOG's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 26, 2026. How the Payback Price works